Prime Medicine (NASDAQ: PRME) — Perfil da empresa, notícias e dados financeiros
Prime Medicine is a biotechnological company utilizing Prime Editing for gene editing therapies targeting serious diseases.
Prime Medicine
Prime Medicine (NASDAQ:PRME) is a biotechnological company focused on harnessing the power of gene editing to develop treatments for serious diseases. The company's operations revolve around the innovative use of Prime Editing, a next-generation gene editing technology, aiming to correct genetic mutations at their source. Prime Medicine is dedicated to advancing its pipeline of projects targeting a wide range of diseases, with the objective of offering transformative therapeutic options to patients in need. The quest to bring novel therapies from the lab to the clinic underscores their commitment to addressing unmet medical needs.
Resumo
Operações
Produtos e/ou serviços de Prime Medicine
- Prime Editing technology, a precise gene editing approach aiming to correct a broad range of genetic mutations.
- Research into treatments for genetic disorders, utilizing prime editing to address diseases at their source.
- Partnerships with biotech and pharmaceutical companies to advance gene editing applications and therapies.
- Development of delivery mechanisms to efficiently target and edit genes within the human body.
- Investment in a scalable platform for the manufacturing and distribution of genetic therapies.
- Ongoing efforts in intellectual property expansion to secure and protect advancements in gene editing technology.
equipe executiva do Prime Medicine
- Jeffrey D. MarrazzoExecutive Chair
- Allan ReineCEO & Director
- Ann L. LeeChief Technical Officer
- Andrew AnzaloneCo-Founder & Head of Platform
- David R. LiuCo-Founder & Member of Scientific Advisory Board
- Svetlana MakhniChief Financial Officer
- Ryan E. BrownChief Legal Officer
- Niamh AlixChief Human Resources Officer
- Mohammed AsmalChief Medical Officer
- Matthew J. HawrylukChief Business Officer
Principais indicadores financeiros
Resultados divulgados pela Prime Medicine , em USD.
- Cap. de mercado
- 972,2 mi
- Receita (TTM)
- 4,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 4,6 mi | -208,4 mi | -201,1 mi | |
| 3 mi | -202,5 mi | -195,9 mi | |
| 0 | -204,8 mi | -198,1 mi | |
| 5,2 mi | -116,5 mi | -121,8 mi |